Jolk's  Instablog

Send Message
Learning quickly about how to invest.
  • High-Sensitivty C Reactive Protein (HsCRP): Yes, Vascepa Lowers This As Well. 2 comments
    May 20, 2013 11:18 PM | about stocks: AMRN

    Yes, Vascepa and Statin reduced hsCRP by 22% versus statin alone in the ANCHOR trial.

    Okay, hsCRP, this was the big research find that led to the successful Crestor (rosuvastatin) JUPITER trial. From the video here:

    Brigham and Women's Hospital researchers found that patients with increased levels of hsCRP (high sensitivity C-reactive protein) are at high risk of heart disease even if their (NYSE:LDL) cholesterol is low.

    hsCRP is a more specific indicator of cardiovascular inflammation compared to the general CRP which is more a marker of systemic inflammation which could be due to a variety of causes, such as infection.

    Read about hsCRP at the Cleveland Clinic:

    Ultra Sensitive C-Reactive Protein Blood (HS-CRP)
    • C-reactive protein measures an inflammatory response in the body and has been shown to play a role in atherosclerosis and blood clot formation.
    • Patients should ask their doctor specifically about hs-CRP, as this test helps determine heart disease risk. Elevated HS-CRP is related to increased risk for heart attack, restenosis of coronary arteries after angioplasty, stroke, and peripheral vascular disease (NYSE:PVD).
    • While elevated cholesterol, LDL and triglycerides and low HDL are all independent risk factors for heart disease and cholesterol build-up, HS-CRP provides additional information about inflammation in the arteries - something not determined by lipid testing alone.

    Since Vascepa (EPA or Eicosapentaenoic Acid) acts to counter the over-active inflammation pathway that is driven by an over-abundance of Arachidonic Acid in our bodies (mainly due to our diets of Omega 6 fatty acids), Vascepa should be expected to lower overall systemic inflammation (NYSE:CRP) as well as the more specific cardio-inflammation marker (hsCRP). This bodes well for seeing actual benefits to patient's cardiovascular health.

    Disclosure: I am long AMRN.

    Stocks: AMRN
Back To Jolk's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
    Thanks Jolk!
    23 May 2013, 05:38 PM Reply Like
  • Jolk
    , contributor
    Comments (309) | Send Message
    Author’s reply » You're welcome.


    Another FYI, Brigham and Women's Hospital has affiliation with Amarin.


    "Deepak L. Bhatt, M.D., M.P.H., Chief of Cardiology at the VA Boston Healthcare System, Director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital and VA Boston Healthcare System, and principal investigator of REDUCE-IT, said "AMR101 has an excellent safety profile and exceeded the expectations for the treatment of high and very high triglyceride levels in the Phase 3 MARINE and ANCHOR trials. Even beyond LDL-C control with statins, there remains a high unmet medical need for the reduction of cardiovascular risk in the patient population with high triglycerides. Importantly, with REDUCE-IT, we anticipate enrolling a significant number of patients with diabetes similar to the population in the ANCHOR trial."

    23 May 2013, 09:50 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.